Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer?

Future Oncol. 2017 Dec;13(28):2503-2505. doi: 10.2217/fon-2017-0405. Epub 2017 Nov 23.

Authors

Monica Cheng¹, Greg Durm², Nasser Hanna², Lawrence H Einhorn², Feng-Ming Spring Kong¹

Affiliations

¹ Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
² Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

PMID: 29168656
DOI: 10.2217/fon-2017-0405

No abstract available

Keywords: NSCLC; PD-1 immune checkpoint inhibition; non-small-cell lung cancer; radiation therapy; radioimmunotherapy; targeted therapy.

Publication types

Editorial
Letter

MeSH terms

Antineoplastic Agents, Immunological / pharmacology
Antineoplastic Agents, Immunological / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / immunology
Carcinoma, Non-Small-Cell Lung / radiotherapy
Combined Modality Therapy
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / immunology
Lung Neoplasms / radiotherapy*
Molecular Targeted Therapy*
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Radiotherapy* / methods
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Programmed Cell Death 1 Receptor